SecBot SecBot
8-K ·Filed Jun 1, 2026

EWTX

Edgewise Therapeutics, Inc.
BULLISH
Impact 8/10
Horizondays Processed5mo ago SEC0001193125-26-249951
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▲ Bullish

The $1.55B upfront cash infusion dramatically de-risks Edgewise's cardiovascular pipeline and provides a clean balance sheet. The stock should re-rate on the cash value alone, the implied cash per share is substantial relative to the current market cap. Key catalysts ahead: CIRRUS-HCM Part D data (Q2 2026) and GRAND CANYON Becker data (Q4 2026) which triggers a $200M milestone. Monitor HSR clearance timeline.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$40.26
T+0 close · Jun 1, 2026 · via day close
Latest settled
+9.81%
T+60 · $44.21
Vs SPY
+8.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $40.26entry
  2. T+1 · 6mo ago −7.48%α −7.62% · $37.25
  3. T+5 · 5mo ago −11.60%α −8.85% · $35.59
  4. T+20 · 5mo ago +0.92%α +2.22% · $40.63
  5. T+60 · 3mo ago +9.81%α +8.58% · $44.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edgewise Therapeutics announced an asset purchase agreement to sell its neuromuscular program, including the sevasemten compound, to Servier for $1.55 billion in upfront cash, plus up to $1.1 billion in regulatory and commercial milestones. The transaction transforms Edgewise into a cardiovascular-focused company, with proceeds expected to fully fund EDG-7500 development through potential approval. The deal is expected to close in Q3 2026, subject to HSR clearance and customary conditions.

Key Financial Metrics

Deal Value
$2.6B
Deal Type
merger

Key Facts

  • Edgewise sells sevasemten and related neuromuscular assets to Servier for $1.55 billion upfront cash.
  • Potential milestone payments up to $1.1 billion: $200M or $100M for Becker approval, $600M for Duchenne approval, $300M for sales milestone.
  • Proceeds fully fund EDG-7500 development through potential approval and strengthen the balance sheet.
  • Edgewise becomes a pure-play cardiovascular company focused on EDG-7500 (Phase 2 HCM), EDG-15400 (Phase 1 HFpEF), and EDG-003 (preclinical).
  • Transaction approved by both boards; expected to close in Q3 2026 subject to HSR clearance.
  • Edgewise to report 12-week CIRRUS-HCM Part D data in Q2 2026.

Financial Impact

$1.55 billion upfront cash plus up to $1.1 billion in milestones, versus a pre-announcement market cap of $3.7B (upfront alone represents ~42% of market cap in cash).

cashrevenuedilutionr&d pipeline

Risk Factors

  • HSR regulatory delay or unexpected antitrust issues could push closing beyond Q3 2026.
  • Milestone payments are contingent on FDA approvals and commercial sales, not guaranteed.
  • Post-transaction, Edgewise's valuation depends entirely on early-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
  • CIRRUS-HCM Phase 2 data risk, if 12-week results are weak, the remaining pipeline thesis is undermined.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-249951
Document: d24037dex991.htm0001193125-26-249951
Document: 0001193125-26-249951-index-headers.html0001193125-26-249951
Document: 0001193125-26-249951-index.html0001193125-26-249951
Document: 0001193125-26-249951.txt0001193125-26-249951

Track record

14 reports on EWTX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today 144 Neutral 1/10 Entry $43.68 Now $43.68 +0.00% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $44.09 Now $43.68 −0.93% settles Feb 12
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  4. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $38.87 Now $43.68 +12.37% settles Feb 3
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.68 Now $43.68 +15.92% settles Feb 1
  6. Aug 14, 202613w ago Insider Cluster Neutral 4/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  7. Aug 14, 202613w ago Insider Cluster Neutral 3/10 Entry $44.04 to $46.53 Now $43.68 −0.82% ▲ +5.65% +8.60% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 7/10 Entry $44.42 to $38.90 Now $43.68 −1.67% ▼ −12.43% −10.76% vs SPY
  9. Jul 13, 202618w ago 8-K Bullish 7/10 Entry $41.27 to $40.02 Now $43.68 +5.84% ▼ −3.03% −7.02% vs SPY
  10. Jun 1, 202624w ago 8-K Bullish 8/10 Viewing Entry $40.26 to $44.21 Now $43.68 +8.49% ▲ +9.81% +8.58% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (9h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026